

Daniel Shasha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9478391/publications.pdf>

Version: 2024-02-01

44
papers

1,816
citations

566801

15
h-index

454577

30
g-index

44
all docs

44
docs citations

44
times ranked

1808
citing authors

#	ARTICLE	IF	CITATIONS
1	Sildenafil Citrate and Risk of Biochemical Recurrence in Prostate Cancer Patients Treated with Radiation Therapy: Post-Hoc Analysis of a Randomized Controlled Trial. <i>Journal of Sexual Medicine</i> , 2021, 18, 1467-1472.	0.3	4
2	Influence of hydrogel spacer placement with prostate brachytherapy on rectal and urinary toxicity. <i>BJU International</i> , 2021, . .	1.3	1
3	Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer. <i>Brachytherapy</i> , 2021, 20, 1099-1106.	0.2	3
4	Management algorithm for HIV-associated parotid lymphoepithelial cysts. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 3355-3362.	0.8	2
5	Oncologic and Toxicity Outcomes after Prostate Brachytherapy for HIV-Positive Patients. <i>Brachytherapy</i> , 2014, 13, S40-S41.	0.2	0
6	Prophylactic Sildenafil Citrate Improves Select Aspects of Sexual Function in Men Treated with Radiotherapy for Prostate Cancer. <i>Journal of Urology</i> , 2014, 192, 868-874.	0.2	70
7	Prostate Cancer Dose Escalation via Simultaneous Integrated Brachytherapy Boost Delivered via Radioactive I125 vs. Pd103 Seeds Followed by External Beam Radiation Therapy. <i>Brachytherapy</i> , 2014, 13, S118-S119.	0.2	0
8	Clinical validation and applications for CT-based atlas for contouring the lower cranial nerves for head and neck cancer radiation therapy. <i>Oral Oncology</i> , 2013, 49, 956-963.	0.8	14
9	Biochemical Outcomes in Patients with Gleason Score 9 or 10 Adenocarcinoma of the Prostate from a Single Institution. <i>Brachytherapy</i> , 2013, 12, S65.	0.2	0
10	Biochemical Outcomes in Patients with Gleason Score 8 Adenocarcinoma of the Prostate from a Single Institution. <i>Brachytherapy</i> , 2013, 12, S69.	0.2	0
11	Exploration of the Role of Radiotherapy in the Management of Early Glottic Cancer with Complete Carotid Artery Occlusion. <i>Onkologie</i> , 2013, 36, 3-3.	1.1	9
12	PSA outcomes in patients with adenocarcinoma of the prostate with presenting PSA > 20 ng/ml.. <i>Journal of Clinical Oncology</i> , 2013, 31, 241-241.	0.8	0
13	Biochemical and functional outcomes of brachytherapy for young men (â%50) with prostate cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 245-245.	0.8	0
14	Contemporary management of localized penile cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 29-36.	1.1	13
15	A Comparison of Post-Implant Day 0 vs Day 30 â€“ Dosimetry forÂLow-Dose-Rate Interstitial Prostate Brachytherapy. <i>Brachytherapy</i> , 2010, 9, S74.	0.2	0
16	Is Low-Dose-Rate Interstitial Brachytherapy for Patients with Large Prostates (>60 cc) Safe and Effective?. <i>Brachytherapy</i> , 2010, 9, S99.	0.2	0
17	1959 SIGNIFICANT AGE DEPENDENCE OF TESTOSTERONE RECOVERY AFTER ANDROGEN DEPRIVATION (ADT) IN PROSTATE CANCER PATIENTS TREATED WITH CURATIVE RADIATION. <i>Journal of Urology</i> , 2010, 183, .	0.2	0
18	A comparison of post-implant day 0 vs. day 30 dosimetry for LDR interstitial transperineal prostate brachytherapy. <i>Brachytherapy</i> , 2008, 7, 180.	0.2	0

#	ARTICLE	IF	CITATIONS
19	Investigation of Epoetin alfa (EPO) 80,000 Units (U) Every 4 Weeks (Q4W) vs. 40,000 U Every 2 Weeks (Q2W) in Patients with Cancer Not Receiving Chemotherapy (CT) or Radiation Therapy (RT): Final Results.. Blood, 2007, 110, 3775-3775.	0.6	0
20	Epoetin alfa 80,000 U Every Three Weeks (Q3W) in Anemic Cancer Patients (pts) Not Receiving Chemotherapy (CT) or Radiation Therapy (RT).. Blood, 2006, 108, 3755-3755.	0.6	0
21	Weekly epoetin alfa treatment of anemia in patients with cancer not undergoing therapy. The Journal of Supportive Oncology, 2006, 4, 129-35.	2.3	1
22	Standard of Care for Cancer-Related Anemia: Improving Hemoglobin Levels and Quality of Life. Oncology, 2005, 68, 22-32.	0.9	19
23	Cancer-Related Anemia: Pathogenesis, Prevalence and Treatment. Oncology, 2005, 68, 3-11.	0.9	156
24	Hematopoietic Response to Extended Dosing of Epoetin alfa 60,000 U Every 2 Weeks in Anemic Cancer Patients Not Receiving Therapy: Final Results.. Blood, 2005, 106, 3764-3764.	0.6	3
25	Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis. Supportive Care in Cancer, 2004, 12, 268-273.	1.0	44
26	Relationship Between Hemoglobin Levels and Quality of Life During Radiation Therapy Plus Concomitant or Sequential Chemotherapy in Patients With Cancer and Anemia Treated With Epoetin Alfa. Journal of the National Comprehensive Cancer Network: JNCCN, 2004, 2, 509-517.	2.3	12
27	Once-weekly dosing of epoetin-? increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer, 2003, 98, 1072-1079.	2.0	98
28	Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer. Journal of Urology, 2003, 169, 2008-2012.	0.2	625
29	15. Dosimetric Coverage Achieved with 125 Permanent Prostate Brachytherapy Often Exceeds Pathologic Estimates of Extraprostatic Tumor Extension. Cancer Journal (Sudbury, Mass), 2003, 9, 488.	1.0	0
30	Adequate Geographic Coverage of Microscopic Extracapsular Tumor Extension Is Usually Achieved with Permanent Pd-103 Prostate Brachytherapy. Cancer Journal (Sudbury, Mass), 2003, 9, 519.	1.0	0
31	Impact of Tumor Hypoxia and Anemia on Radiation Therapy Outcomes. Oncologist, 2002, 7, 492-508.	1.9	320
32	Prevalence of Anemia in Cancer Patients Undergoing Radiotherapy: Prognostic Significance and Treatment. Oncology, 2002, 63, 11-18.	0.9	49
33	An Internet-ready database for prospective randomized clinical trials of high-dose-rate brachytherapy for adenocarcinoma of the prostate. International Journal of Radiation Oncology Biology Physics, 2002, 53, 104-115.	0.4	2
34	The negative impact of anemia on radiotherapy and chemoradiation outcomes. Seminars in Hematology, 2001, 38, 8-15.	1.8	32
35	The American Brachytherapy Society recommendations for brachytherapy of soft tissue sarcomas. International Journal of Radiation Oncology Biology Physics, 2001, 49, 1033-1043.	0.4	102
36	Thermoluminescent dosimetry of the Symmetraâ„¢ 125I model I25.S06 interstitial brachytherapy seed. Medical Physics, 2001, 28, 1761-1769.	1.6	45

#	ARTICLE	IF	CITATIONS
37	The negative impact of anemia on radiotherapy and chemoradiation outcomes. Seminars in Hematology, 2001, 38, 8-15.	1.8	24
38	Prevalence of anemia in cancer patients undergoing radiation therapy. Seminars in Oncology, 2001, 28, 54-59.	0.8	6
39	The role of brachytherapy for palliation. Seminars in Radiation Oncology, 2000, 10, 222-239.	1.0	7
40	Radiotherapy-Associated Anemia: The Scope of the Problem. Oncologist, 2000, 5, 1-7.	1.9	109
41	Radiotherapy-Associated Anemia: The Scope of the Problem. Oncologist, 2000, 5, 1-7.	1.9	9
42	BRACHYTHERAPY IN THE TREATMENT OF COLORECTAL MALIGNANCIES. Hematology/Oncology Clinics of North America, 1999, 13, 559-575.	0.9	1
43	The role of brachytherapy in head and neck cancer. Seminars in Radiation Oncology, 1998, 8, 270-281.	1.0	15
44	ELECTIVE IRRADIATION OF THE NO NECK IN SQUAMOUS CELL CARCINOMA OF THE UPPER AERODIGESTIVE TRACT. Otolaryngologic Clinics of North America, 1998, 31, 803-813.	0.5	21